Avalo Therapeutics (AVTX) Return on Sales (2016 - 2025)
Historic Return on Sales for Avalo Therapeutics (AVTX) over the last 11 years, with Q3 2025 value amounting to 520.2%.
- Avalo Therapeutics' Return on Sales fell 6127200.0% to 520.2% in Q3 2025 from the same period last year, while for Sep 2025 it was 520.2%, marking a year-over-year decrease of 5104900.0%. This contributed to the annual value of 79.66% for FY2024, which is 632600.0% down from last year.
- As of Q3 2025, Avalo Therapeutics' Return on Sales stood at 520.2%, which was down 6127200.0% from 104.8% recorded in Q2 2025.
- In the past 5 years, Avalo Therapeutics' Return on Sales registered a high of 165.56% during Q1 2025, and its lowest value of 520.2% during Q3 2025.
- In the last 5 years, Avalo Therapeutics' Return on Sales had a median value of 6.52% in 2021 and averaged 42.5%.
- Data for Avalo Therapeutics' Return on Sales shows a peak YoY increase of 2641000bps (in 2025) and a maximum YoY decrease of -6127200bps (in 2025) over the last 5 years.
- Avalo Therapeutics' Return on Sales (Quarter) stood at 0.3% in 2021, then skyrocketed by 99bps to 0.0% in 2022, then crashed by -382254bps to 14.3% in 2023, then plummeted by -1187bps to 184.06% in 2024, then plummeted by -183bps to 520.2% in 2025.
- Its last three reported values are 520.2% in Q3 2025, 104.8% for Q2 2025, and 165.56% during Q1 2025.